> > >
Ceva expands oral rabies vaccine portfolio with the acquisition of Canadian firm Artemis Technologies, Inc.

Ceva expands oral rabies vaccine portfolio with the acquisition of Canadian firm Artemis Technologies, Inc.

This strategic acquisition complements Ceva’s rabies portfolio.

Libourne, May 16, 2022 – Ceva Santé Animale (Ceva) has acquired the Canadian oral rabies vaccine manufacturer Artemis Technologies, Inc.

Artemis, located in Guelph, ON, Canada, produces ONRAB®, a rabies glycoprotein recombinant oral vaccine licensed for use in striped skunks (Mephitis mephitis) in Canada. The product also had positive field trial use in the USA in wild raccoons and skunks.

"Ceva’s business purpose includes a commitment to One Health and caring for all animals. With this acquisition, we will help protect humans, wildlife, pets and livestock from the devastating effects of this lethal zoonotic disease. We are pleased to finalize this acquisition which aligns with our goal to expand our efforts in wildlife disease management."

said Marc Prikazsky, President and CEO of Ceva Santé Animale.

This strategic acquisition complements Ceva’s rabies portfolio and considerable experience in rabies oral vaccine production and management of oral rabies vaccination campaigns in Europe and elsewhere. With this acquisition, Ceva will expand its presence in the segment to North America.

"Since founding Artemis in 1997, our team has worked in partnership with government authorities to help eliminate rabies in wildlife as part of their rabies management programs. We are convinced that Ceva will be able to expand on Artemis’ success and continue to work with our government partners to develop innovative solutions to combat rabies in wildlife. We look forward to watching Artemis grow under Ceva’s leadership."

said Alex Beath, Artemis Owner, and President.

>> Download PDF version

Also in the News & Media section

Back to top